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Background: The adipose tissue is an endocrine regulator and a risk factor for atherosclerosis and cardiovascular
disease when by excessive accumulation induces obesity. Although the adipose tissue is also a reservoir for stem
cells (ASC) their function and “stemcellness” has been questioned. Our aim was to investigate the mechanisms by
which obesity affects subcutaneous white adipose tissue (WAT) stem cells.
Results: Transcriptomics, in silico analysis, real-time polymerase chain reaction (PCR) and western blots were
performed on isolated stem cells from subcutaneous abdominal WAT of morbidly obese patients (ASCmo) and of
non-obese individuals (ASCn). ASCmo and ASCn gene expression clustered separately from each other. ASCmo
showed downregulation of “stemness” genes and upregulation of adipogenic and inflammatory genes with respect
to ASCn. Moreover, the application of bioinformatics and Ingenuity Pathway Analysis (IPA) showed that the
transcription factor Smad3 was tentatively affected in obese ASCmo. Validation of this target confirmed a
significantly reduced Smad3 nuclear translocation in the isolated ASCmo.
Conclusions: The transcriptomic profile of the stem cells reservoir in obese subcutaneous WAT is highly modified
with significant changes in genes regulating stemcellness, lineage commitment and inflammation. In addition to
body mass index, cardiovascular risk factor clustering further affect the ASC transcriptomic profile inducing loss of
multipotency and, hence, capacity for tissue repair. In summary, the stem cells in the subcutaneous WAT niche of
obese patients are already committed to adipocyte differentiation and show an upregulated inflammatory gene
expression associated to their loss of stemcellness.
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White adipose tissue (WAT), traditionally viewed as an
energy storage tissue, is now recognized as an endocrine
organ that harvests and serves as repository of mesen-
chymal stem cells, the adipose-derived stem cells (ASC),
for physiological cell renewal and spontaneous repair.
Henceforth, these ASC have the potential to differentiate
towards multiple tissue lineages, produce a large variety
of growth factors and present immunomodulatory prop-
erties [1]. Mesenchymal stem cells (MSC) homing from
bone marrow to peripheral tissue is probably the most
specialized organ repairing process. During the last few
years it has been possible to isolate MSC from different
tissues [2].
Obesity, a chronic pathological condition, is a risk fac-
tor for cardiovascular disease, but paradoxically, it seems
to protect against morbi/mortality from heart failure [3].
The hypothesis of a repository of stem cells in WAT of
heart failure-obese patients that may serve as a source
for spontaneous repair has never been tested. It has been
recently suggested that any alteration of the stem cell
homeostasis by constant and repetitive trauma, and
chronic disease could provoke a persistent disequi-
librium inside the stem cell reservoir leading to an
irreversible and premature decrease of the stem cells
regenerative potential reducing their “stemcellness” [2].
Because a growing body of evidence suggests that depot-
specific variations in resident stem cells are retained
despite in vitro culture processes [3], we investigated the
isolated stem cells from the adipose tissue niches to
identify their changes due to obesity. Indeed, we have
previously reported that adipose-derived stem cells
(ASC) from obese patients show a differentiation poten-
tial and are less proangiogenic than ASC from non-
obese individuals [4]. However, how obesity affects ASC
and which are the affected genes remain unclear.
Differences in gene expression between subcutaneous
and visceral WAT have been reported. As such, genes
involved in energy homeostasis and adipogenesis are
profoundly altered in obese WAT [5-8]. Additionally,
in obese individuals’ mature adipocytes, the major
WAT-cell types have shown to present an altered
inflammation-related gene expression profile [9]. In
addition, studies in subcutaneous preadipocytes from
type 2 diabetes patients and obese Pima Indian
subjects have reported diminished expression of genes
involved in differentiation and an upregulation of
inflammation-related genes [10,11]. Moreover, obesity
has shown to dysregulate the stemness gene network
of omental-ASC [12]. However, there are few studies
investigating how obesity affects the transcriptome of
resident stem cells reservoir.
In this study, we investigated the gene expression
profile and the involved biological functions in ASC ofobese patients using a systems biology approach. ASC
were isolated from WAT to avoid the contribution of
differentiated cells in subcutaneous WAT to the trans-
criptomic signature. We studied gene expression profile
of isolated subcutaneous ASC from patients with obesity
and clustering of cardiovascular risk factors and ASC
from non-obese healthy individuals. We used a bioin-
formatic approach with “in silico” analysis to identify
biological functions and target genes potentially altered
in ASC. Further validation of candidate genes has identi-
fied potential targets associated to a reduced regenera-
tive potential.
Results
Patient demographics and ASC phenotypic
characterization
ASC were harvested from morbidly obese patients
[Body mass index (BMI) = 44.44 ± 1.29 kg/m2], and non-
obese individuals (BMI = 22.26 ± 0.88 kg/m2). Although
both groups were comparable in age (morbidly obese pa-
tients = 41.56 ± 3.07 years; non-obese individuals = 38.28 ±
2.48 years), morbidly obese patients showed significantly
(p < 0.05) elevated glucose (142.13 ± 11.95 mg/dl vs
61.54 ± 7.35 mg/dl), creatinine levels (0.83 ± 0.07 mg/dl
vs 0.55 ± 0.1 mg/dl) and total cholesterol/high density
lipoprotein cholesterol (HDL) ratio (5.92 ± 0.48 vs 3.98 ±
0.38), and lower HDL cholesterol levels (33.2 ± 3.05 mg/dl
vs 48.32 ± 2.82 mg/dl) as compared to non-obese indi-
viduals. No differences were detected in triglyceride, total
cholesterol, low density lipoprotein cholesterol (LDL),
urea, total proteins and hepatic enzymes levels.
Flow cytometry analysis of isolated ASC from mor-
bidly obese patients (ASCmo) and non-obese individuals
(ASCn) revealed similar ASC phenotype in both groups
of cells at passage 3, when the transcriptomic analysis
was performed. Both cell types strongly expressed typical
ASC surface antigens such as CD90 (Thy-1 cell surface
antigen), CD29 (Integrin beta 1), CD44 (Hyaluronic acid
receptor), and CD105 (Endoglin) and were negative for
CD45, a hematopoietic cell marker, and for CD34, a
marker of bone marrow cells, hematopoietic stem cells,
endothelial progenitor cells and muscle stem cells
(Additional file 1: Table S1). Interestingly the flow cy-
tometry analysis at passage 0 demonstrated that passage
3 cells had similar ASC surface markers levels (CD105,
CD29, CD90 and CD44) with respect to passage 0 cells.
However, a significant reduction in CD34 and CD45 was
found indicating that the passage 3 cells used for
transcriptomic analysis were a homogeneous ASC popu-
lation (Additional file 1: Table S1).
Transcriptomic analysis
In order to compare gene expression patterns between
ASCmo and ASCn, a comprehensive transcriptomic
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expression array. To visualize gene expression data we
performed Principal Component Analysis (PCA) that dem-
onstrated the independence of transcriptomic signature in
ASCmo and ASCn (Additional file 2: Figure S1). To further
explore genes differentially expressed between ASCmo and
ASCn, we used modified analysis of variance (ANOVA)
analysis. With a p-value < 0.2, a 60% False Discovery Rate
(FDR) and a fold change > 1.5, 637 differentially expressed
transcripts were detected while with a p-value < 0.1, a 60%
FDR and a fold change > 1.5, 457 gene transcripts were
detected (Additional file 3: Figure S2). Among the 637
detected genes, 319 exhibited an increased expression
in ASCn (fold change range: 1.5 to 7.2) while 318
were overexpressed in ASCmo (fold change range: 1.5
to 18).
ASCmo and ASCn gene expression patterns
Ingenuity Pathway Analysis (IPA) data identified the most
relevant modifications in gene expression in ASCmo. These
genes were further validated by real-time PCR (Figure 1).
Developmental genes were down-regulated in the ASCmoDevelopmental genes
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was observed in HOXC10 (Homeobox C10; -1.42 fold),
TBX15 (T-box 15; -2.04 fold), ACTA2 (α-smooth muscle
actin; -1.42 fold) and SDF-1 (Stromal cell-derived factor
1/CXCL12; -2.32 fold) (Figure 1A).
Moreover, ASCmo presented a significant up-regulation
in genes that induce adipocyte lineage commitment or
regulates adipogenesis, such as TCF21 (Transcription
factor 21; 2.62 fold), PITX2 (Paired-like homeodomain
transcription factor 2; 1.88 fold), LIF (Leukemia inhibitory
factor; 4.4 fold), TNFRSF11B (Osteoprotegerin; 15.23 fold)
and HAPLN1 (Hyaluronan and proteoglycan link protein
1; 2.94 fold). Contrary RUNX2 (Runt-related transcription
factor 2; -1.4 fold), that induces osteoblastogenesis,
showed a trend towards a decrease expression in ASCmo
compared to ASCn (Figure 1B).
There was an up-regulation in the expression of pro-
inflammatory molecules such as IL-1β (Interleukin-1β;
4.81 fold), IL-8 (Interleukin-8; 5.9 fold) and CCL2 (mono-
cyte chemotactic protein-1; 3.35 fold), and OLR1 (oxidized
low density lipoprotein receptor 1; 7.62 fold) in
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http://www.biomedcentral.com/1471-2164/14/625DAPK1 (Death-associated protein kinase 1, -2.40) is
down-regulated in ASCmo compared to ASCn
(Figure 1C).
Effects of cardiovascular risk factor clustering
Correlation analysis between gene expression and BMI
or clustering of cardiovascular risk factors (morbid
obesity, high blood pressure, smoking, previous cardio-
vascular event, dyslipidemia and/or type 2 diabetes) wasG
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Figure 2 Correlation between expression of validated genes and bod
linear correlations.performed. Expression levels of ACTA2 (R: -0.69),
TBX15 (R: -0.68), SDF-1 (R: -0.46) and DAPK1 (R: -0.43)
negatively correlated with BMI increase (p < 0.05);
whereas LIF (R: 0.46), PITX2 (R: 0.44), TNFRSF11B
(R: 0.58), IL-1β (R: 0.45) and OLR1 (R: 0.51) correlated
positively (p < 0.05) (Figure 2). Furthermore, ACTA2 (Rho:
-5.97), HOXC10 (Rho: -5.29) and TBX15 (Rho: -0.671)
negatively correlated with cardiovascular risk factor clus-
tering (p < 0.05); while LIF (Rho: 0–477), PITX2 (Rho:BMI 
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http://www.biomedcentral.com/1471-2164/14/6250.459), OLR1 (Rho: 0.485), TNFRSF11B (Rho: 0.805), IL-1β
(Rho: 0.52) and IL-8 (Rho: 0.644) correlated positively
(p < 0.05) (Figures 3 and 4).
SMAD activation differs between ASCn and ASCmo
Bioinformatic systems biology analysis predicted the
SMAD pathway as a potential candidate in the activa-
tion/repression of the modified genes in obesity. In order
to analyze SMAD pathway activation, we assessed
nuclear translocation of phospho-Smad3. We show that
ASCmo present a lower activation of SMAD pathway, in
fact, phospho-Smad3 nuclear translocation were signifi-
cantly reduced in the ASCmo (Figure 5).
Discussion
In this study we demonstrate that obesity affects WAT-
resident ASC by differentially regulating their gene
expression. The transcription of both genes involved in
development as well those involved in adipocyte diffe-
rentiation is significantly modified. Moreover, ASC from
obese patients already show upregulation of inflamma-
tory genes. Interestingly, ASC from obese patients with
metabolic syndrome (and clustering of cardiovascular
risk factors) show further impairment in their trans-
criptomic profile than ASC from obese metabolically
healthy patients.
ASC in morbidly obese patients show similar ASC
surface markers (CD44, CD90, CD29 and CD105) to
ASC from non-obese individuals. However, we had pre-
viously shown that ASCmo have significantly different
cell proliferation, differentiation and angiogenic potential
[4]. Here we show that ASC from the subcutaneous
WAT of morbidly obese patients adopt a significantly
modified expression profile with major changes on genes
that regulate cell survival, cell differentiation, tissue
integrity and metabolic pathways. Interestingly, the ASCA B
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genes in ASC. Correlation significances between gene expression and num
Spearman correlation (* p < 0.05).(passage 3; both from non-obese and obese patient
abdominal fat) were negative for the surface marker
CD34, a marker described for bone marrow cells,
hematopoietic stem cells, endothelial progenitor cells
and muscle stem cells [13]. In fact, the expression of
CD34 by ASC has been a matter of discussion because
of contradictory reports and findings [14]. While some
authors have described an ASC population that express
CD34 [15-17], some others have not been able to detect
this marker [1,18,19].
Two highly conserved families of genes involved in
embryonic development show down-regulation in ASC
from morbidly obese patients: the homeobox (HOXC10)
and T-box (TBX15). The HOX code is mainly a “bio-
logical fingerprint” of different cell types reflecting a
continuation of embryonic patterning [20]. Despite the
essential role played by HOX genes in embryonic deve-
lopment, hematopoiesis, cancer, angiogenesis and wound
repair, there is limited information on HOX genes in a
variety of MSC. Similarly, Tbx15 is one of the funda-
mental developmental mesodermal transcription factors
that is highly expressed in both human and rodent
adipose tissue [21]. Here we described for the first time
that obesity down-regulates expression of TBX15 and
HOXC10 in subcutaneous WAT resident stem cells. The
expression of both genes negatively correlates with BMI
and cardiovascular risk factor clustering therefore poten-
tially marking a reduced developmental potential of the
more differentiated cells of the morbid obesity fat depot.
The same result is shown with ACTA2, an ASC gene
marker. It has been shown that mice ASC expressing
ACTA2 present multilineage differentiation ability com-
pared to ASC that do not express ACTA2 which only
display adipogenic commitment [22]. The fact that
expression of these three genes are found significantly
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stem cells homed into their subcutaneous WAT.
Stem cell migration is a key process for development,
spontaneous regeneration and homing. It has been de-
scribed that the CXCR4-SDF-1 axis regulates cellularA
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Figure 5 Nuclear translocation of phospho-Smad3 differs between AS
(C) and nuclear (N) fraction of ASCn and ASCmo. β-tubulin and Histone H1
respectively. (B) ASCmo presented a reduced nuclear translocation of phostrafficking [23] and that ASC produce and secrete SDF-1
[24]. Circulating SDF-1 levels are decreased in diet-
induced obese mice and in adolescents with elevated
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and that the effect is BMI-dependent and correlates with
cardiovascular risk factors clustering. These results
indicate that obesity seems to impair ASC trafficking
and homing.
Given that adipocytes share a common mesenchymal
precursor cell with osteoblasts, entrance into the adipo-
cytic or osteoblastic lineage is thought to be mutually
exclusive [26]. In fact, our results revealed that the
adipogenic lineage is stimulated in ASCmo while
osteoblastogenesis is inhibited. We have observed that
TCF21 expression, a white WAT-selective marker, is
increased in ASCmo. Opposite, RUNX2, an osteoblast
marker, presented a non-significant trend to decrease in
ASCmo. TCF21 is the first useful positive selection
marker for white preadipocytes and plays an important
role in adipogenesis. It has been shown that TCF21
suppresses myogenesis [27]. Of interest, PITX2 that is
known to upregulate the expression of TCF21 [28], is
up-regulated in ASCmo explaining the increase in
TCF21 expression.
On the other hand, we detected that ASCmo presented
an increased expression in LIF and TNFRSF11B genes.
Various studies of LIF in adipose tissue have suggested
that adipogenesis could be modulated by this gp130
cytokine at certain stages of development while regulating
the expression of genes associated with lipid metabolism
[29]. Furthermore, TNFRSF11B (Osteoprotegerin) is a gly-
coprotein of the tumor necrosis factor (TNF) receptor
superfamily that was originally discovered as bone resorp-
tion inhibitor [30]. Its expression is high in human WAT,
and is increased during 3T3-L1 adipocyte differentiation
and under TNF-α and IL-1β stimulation [31]. In humans,
plasma TNFRSF11B levels are elevated in patients with
cardiovascular risk factors such as type 2 diabetes and
abdominal obesity [32]. We have also detected that both
LIF and TNFRSF11B levels positively correlate with BMI
and the clustering of cardiovascular risk factors. Moreover,
RUNX2 is involved in inhibiting adipocyte differentiation
and appears to be down-regulated during 3T3-L1 adipo-
cyte differentiation [33] and obesity reduces bone RUNX2
expression leading to bone marrow adiposity [34]. Inte-
restingly, it has been published that ASC from WAT of
obese patients show abnormal upregulation of peroxisome
proliferator-activated receptor-γ (PPARG), a gene that
reveals a high adipogenic potential [12,35]. All together
these observations indicate that morbid obesity not only
affects ASC multilineage potential but commit ASC to
adipogenic lineage.
Recent studies demonstrate that during adipogenesis
and development of obesity, the extracellular matrix
(ECM) undergoes structural remodeling affecting adi-
pose tissue expandability and functional integrity [36].
Analysis of the secretome of human ASC identifiedvarious components of the ECM synthesis and remo-
deling [37]. The glycosaminoglycan hyaluronan is an
integral component of ECM with an important role in
organizing and maintaining the integrity of the ECM.
Although hyaluronan regulates differentiation of mesen-
chymal lineage cells to chondrocytes and osteoblasts
[38], it has been also shown that hyaluronan increases
adipogenesis efficiency likely because it provides an
appropriate ECM [39]. In fact, it has been demonstrated
that hyaluronan synthesis, in 3T3-L1, appears at the
stages where early adipocyte markers develop and corre-
lates with triglyceride accumulation [40]. Interestingly
we have detected in ASCmo higher levels of HAPLN1, a
member of the hyaluronan and proteoglycan binding
link protein gene family that stabilizes the interaction
between hyaluronan and versican, two ECM components
that contribute to the viscoelastic properties observed
during 3T3-L1 adipogenic differentiation [40]. More
experiments are needed to address how obesity and
cardiovascular risk factors modify the adipose tissue
ECM and its expandability.
Obesity is associated with a low-grade chronic inflam-
mation [41]. Paracrine and autocrine signaling in WAT-
cells may further enhance inflammation, ultimately
increasing proinflammatory cytokines production [41].
Yet, it seems that adipocytes and mainly stromal vascu-
lar cells appear to be involved in the local production of
such cytokines [11,42]. Here we show that obesity
induces inflammatory gene up-regulation already in the
stem cells. IL-1β, IL-8 and CCL2 genes are up-regulated
in ASCmo. In fact, while we detected that IL-1β increase
is affected by BMI, IL-8 expression is correlated with
cardiovascular risk factors clustering. IL-1β and IL-8 are
considered the prototypical proinflammatory cytokines
involved in stimulating the synthesis and secretion of a
variety of other interleukins, and also participates in a
variety of cell functions [42]. Furthermore, high circula-
ting levels of IL-8 and CCL2 have been found in obese
subjects increasing the risk of coronary artery disease
and type 1 or 2 diabetes [43]. In fact, IL-8 released from
subcutaneous WAT and omental-ASC displayed a posi-
tive correlation with BMI [12,44], whereas CCL2 expres-
sion was higher in subcutaneous adipocytes of obese
than non-obese Pima Indians [9].
Furthermore, we report for the first time that ASCmo
show increased expression of OLR1 (LOX-1), a lectin-
like receptor for oxidized-LDL. OLR1 is expressed in
highly vascularized tissues, plays critical roles in the
development of atherosclerosis and related disorders,
and is upregulated in hypertensive, dyslipidemic, and
diabetic animals and humans [45,46]. A recent study
reported that oxidized-LDL-Olr1 interaction induces the
generation of reactive oxygen species and stimulates
pro-inflammatory gene expression [47]. Thus, the effects
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of inflammation and adipocyte death. In this study we
identified that although OLR1 expression levels in ASC
is low, morbid obesity and clustering of cardiovascular
risk factors significantly increases ASC OLR1 expression.
Finally, we have observed a significantly reduced
expression of DAPK1 in ASCmo. The death-associated
protein kinase-1 (DAPK1) is the prototypic member of a
family of death-related kinases. However, DAPKs can
also act as a survival factors and block apoptosis in
response to certain cytokine signals modulating the
balance between pro-apoptotic and pro-survival path-
ways [48].
To address the signaling pathways differentially acti-
vated in ASCmo, the validated gene expression data was
analyzed in silico with the IPA software to obtain the
most probable networks and biological pathways. Candi-
date proteins identified by IPA were validated by western
blot. As such, a lower activation of Smad3 was found in
the stem cells of the subcutaneous WAT of obese pa-
tients. Interestingly, the transcription factor Smad3 plays
a key role in the inhibition of adipocyte differentiation
and in the development of insulin resistance [49,50].
This integrated bioinformatic systems biology approach
led us to propose a network that regulates the diffe-
rential gene expression pattern in stem cells found in
subcutaneous fat of morbidly obese patients (Figure 6).
Our data does not help to explain the obesity paradox.
Indeed, studies of patients with chronic heart disease
suggest that overweight and obese patients may para-
doxically have better outcomes than lean patients. ThisFigure 6 Hypothetical network proposed to explain the differentially
done using Ingenuity Pathways Analysis.results may associate adiposity with enhanced cardio-
vascular autoreparative potential [51]. However our
previous results [4] and these here reported indicate that
obesity renders ASC less multipotent leaving the
paradox unsolved. An alternative not yet fully explored
possibility is that obesity could promote MSC recruit-
ment in order to perpetuate adipose tissue formation
[2], and consequently lead to increase number of circu-
lating MSC which in turn, upon organ damage, could
migrate to the site of injury for repair [52].
Conclusions
In summary, obesity produces a detrimental effect on its
resident stem cells. In fact, the ASC undifferentiated
multipotent state is impaired in obese patients with
respect to non-obese individuals. This study provides a
global systems biology analysis of highly modified genes
expressed in ASC from patients with obesity and cardio-
vascular risk factor clustering that shows how the WAT
niche affect resident stem cells. A remaining question
that deserves further investigation is whether obesity
affects the mesenchymal stem cell transcription potential
in the adipose tissue reservoir or stem cells are already
conditioned by obesity in the patient’s bone marrow.
Methods
Subjects
Subcutaneous abdominal WAT was obtained via surgical
resection from morbidly obese patients (BMI > 40 kg/m2;
n = 16) that underwent bypass gastric surgery, and
from non-obese individuals (BMI < 25 kg/m2; n = 8)expression pattern between ASCmo and ASCn. The network was
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obtained with informed consent and the study proto-
col was approved by the Centro Medico Teknon’s
Ethical Committee consistent with the principles of
the Declaration of Helsinki. Blood samples from all
subjects were obtained at the time of intervention in
order to evaluate the following biochemical parame-
ters: glucose, triglyceride, total cholesterol, HDL, LDL,
urea, total proteins, glutamic oxaloacetic transaminase,
glutamic pyruvic transaminase, and creatinine levels.
Patients used regular medication as recommended in the
guidelines if it was necessary. In order to analyze the effect
of cardiovascular risk factors (morbid obesity, high blood
pressure, smoking, dyslipidemia, type 2 diabetes and/or
previous cardiovascular event), individuals were clustered
according to the accumulated cardiovascular risk factors:
0) non-obese individuals, 1) morbid obesity, 2) morbid
obesity and one additional risk factor (high blood pressure
or dyslipidemia), ≥3) morbid obesity and two or more risk
factors (patients with metabolic syndrome).
ASC isolation and culture
Isolation of ASCmo and ASCn was performed as we
have previously described [4]. Briefly, AT was washed,
minced and digested with 1 mg/ml Collagenase I-A
(Sigma-Aldrich; St. Louis, MO, USA) in Dulbecco’s
modified Eagle’s Medium high glucose (Gibco; Life
Technologies, Inc., Grand Island, NY, USA) for 1 h at
37°C with gentle agitation. The digested tissue was
sequentially filtered through a 100 μm mesh and
centrifuged for 10 min at 1200 rpm at room tempe-
rature. The supernatant, containing mature adipocytes,
was aspirated and the pellet was identified as the stromal
vascular fraction (SVF). SVF was resuspended in culture
medium (Dulbecco’s modified Eagle’s Medium supple-
mented with 10% fetal bovine serum, 100 U/ml penicil-
lin and 100 μg/ml streptomycin; Life Technologies,
Paisley, UK) and seeded at 2×105cells/cm2. Finally, these
cells were incubated overnight at 37°C, 5% CO2 under
hypoxic conditions (1% O2); 24 h after incubation, the
medium was changed to remove non-adherent cells.
These primary adherent cells are referred as ASC pas-
sage 0 (cultured for 7 days until they reached 75-90%
confluence). For further passages cells were detached by
trypsin digestion.
Flow cytometry characterization
For further characterization, cell surface antigen pheno-
type was performed on ASCmo and ASCn at passage 0
and passage 3. The following cell-surface epitopes were
marked with anti-human antibodies: CD105-fluorescein
isothiocyanate (GeneTex), CD90-fluorescein isothio-
cyanate (FITC), CD29-phycoerythrin (PE), CD44-FITC,
CD34-PE-Cy™5 and CD45-PE (BD Biosciences; SanDiego, CA, USA). Mouse isotype antibodies served as
control (BD Biosciences). Cellular events (30000) were
acquired and analyzed by Fluorescence-activated cell
sorting using Coulter EPICS XL flow cytometer
(Beckman Coulter) running Expo32 software (Beckman
Coulter).
Transcriptomic analysis
The whole genome expression was assessed by
independently run microarrays in isolated human
ASCmo (n = 3) and ASCn (n = 3) cultured under hypoxic
conditions (passage 3) using GeneChip Human Gene 1.0
ST arrays (Affymetrix; Santa Clara, CA, USA). Total cell
RNA was extracted using silica-membrane columns
(RNesasy Mini Kit, Qiagen; Valencia, CA, USA). RNA
quantification was determined spectrophotometrically
using the Nanodrop ND-1000 (Thermo Fisher Scientific;
Whaltham, MA, USA). RNA quality was measured using
Agilent 2100 Bioanalyzer technology (Agilent Technolo-
gies; Santa Clara, CA, USA) with the Agilent RNA 6000
Nano Kit (Agilent Technologies). Only RNA samples
with RIN > 7 (RNA integrity number) values were
chosen for microarray experiments. Using the Ambion
WT Expression Kit (Ambion, Life Tecnologies, Paisley,
UK) 200 ng of total RNA (mixed with poly-A controls;
Affymetrix) were converted to double strand DNA, in
two steps, in order to obtain cRNA by an in vitro tran-
scription. Single strand DNA was obtained from 10 ug
of cRNA. Then 5.5 ug of single strand DNA were
fragmented and labelled with biotin using the WT Ter-
minal Labeling Kit (Affymetrix). Hybridization controls
from the Hybridization, Wash and Stain Kit (Affymetrix)
were added to the sample. Every sample was hybridized to
GeneChip Human Gene 1.0 ST array during 16 h at 45°C
and 60 rpm, according to manufacturer’s instruccions.
Hybridization, washing, staining and scanning of
microarrays were performed according to Affymetrix
instructions using the Affymetrix GeneChip 3000 7G
System (645 Hybridization Oven, 450 Fluidic Station
and GeneChip 3000 7G Scanner).
Raw data were pre-processed with Robust Multiarray
Average (RMA) method [53]: background correction,
quantile normalization and median polish summari-
zation of the probes. Bioinformatics was used to analyze
the extracted log2 expression data. The raw data from
the array experiments has been deposited in NCBI’s
Gene Expression Omnibus [54] and is accessible through
GEO Series accession number (GSE48964; http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48964).
Microarray quality control and statistical analyses were
performed using the Partek Genomics Suite software
(Partek Inc., St Louis, Miossouri, USA). PCA procedure
was used to represent samples variability, which defines
a group of Principal Components in order to explain the
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fied by Partek Inc, was used for statistical comparisons
between groups. Derived p-values were adjusted for
multiple testing with the method of Benjamini and
Hochberg [55]. Adjusted p-value, FDR <0.6 and fold
change ≥ ±1.5 were used to obtain differential expressed
genes. Some of the modified genes were validated using
real-time PCR in ASC from additional non-obese
individuals (n = 8) and morbidly obese patients (n = 16).
Differential expressed genes were associated with bio-
logical functions and/or diseases based on literature and
the Ingenuity Knowledge Base. Differential expressed
genes were analyzed through the use of IPA (Ingenuity®
Systems, www.ingenuity.com). Right‐tailed Fisher’s exact
test was used to calculate a p‐value determining the
probability that each biological function and/or disease
assigned to that data set is due to chance alone. The data
set from our study was used to construct hypothetical
protein interaction based on a regularly updated Ingenuity
Pathways Knowledge Base. The networks are displayed
graphically as nodes (individual proteins) and edges (the
biological relationships between the nodes). The relation-
ships include direct and indirect protein interactions.
Real time PCR validation
In order to validate the generated data, genes of interest
that showed a statistically significant difference in expres-
sion were validated using custom Taqman Low Density
Arrays and real-time PCR assays according to manu-
facturer’s instructions (Applied Biosystems, Life Technolo-
gies). Relative gene expression values were calculated by
the ΔΔCt method [56]. The raw gene expression values
were normalized according to the expression of TATA-
binding protein (TBP) gene.
Western blotting
ASC subcellular fractionation and western blot analysis
were performed to analyze proteins levels and nuclear
translocation in non-obese individuals (n = 7) and mor-
bidly obese patients (n = 9).
Subcellular fractionation analysis was performed to
evaluate phoshpo-Smad3 nuclear translocation. Nuclear
and membrane-cytoplasmic proteins were extracted
from ASCn and ASCmo cultured under hypoxic condi-
tions as previously described [57]. The extraction was
performed on ice to avoid denaturation of the proteins.
Equivalent amounts of proteins were subjected to
electrophoresis on 10-12% gels and then transferred to
nitrocellulose membrane. After blocking in 5% nonfat
milk 1 h at room temperature, blots were incubated with
anti-phospho-Smad2/3 goat polyclonal (Santa Cruz
Biotechnology; Santa Cruz, CA, USA), anti-β-tubulin
rabbit polyclonal (Abcam; Cambridge, UK) and anti-
Histone H1 mouse monoclonal (Millipore; Billerica, MA,USA) at 4°C overnight. Secondary antibodies consisted
of horseradish peroxidase-conjugated antibodies (Dako;
Barcelona, Spain) and were detected using SuperSignal
chemiluminescence system (Pierce; Rockford, IL, USA).
β-tubulin and Histone H1 were used as a membrane-
cytoplasmic and nuclear fraction marker, respectively.
Protein expression was determined using Image LabTM
Software (BIO RAD). Nuclear translocation was calculated
as a relation between nuclear protein vs total protein
(nuclear +membrane/cytoplasmic protein) quantification.
Additional statistical analyses
Results are expressed as means ± standard error mean.
Statistical Analyses were performed using StatView® soft-
ware (SAS Institute Inc.). The statistical significance was
assessed by unpaired Student’s t-test. Correlation analyses
between gene expression and BMI or number of cardio-
vascular risk factors were determined by linear regression
and Spearman correlation, respectively. P-value < 0.05 was
considered statistically significant.
Additional files
Additional file 1: Table S1. Phenotypical characterization of ASC.
Flow cytometry analysis of ASCn and ASCmo at passage 0 and 3 were
performed in order to characterize ASC populations. Data are presented
as means ± standard error mean.
Additional file 2: Figure S1. Principal component analysis (PCA) of
genomic expression data from ASC from different donors.
Additional file 3: Figure S2. Heat map of genes displaying 1.5-fold
difference in expression between ASC individuals groups.
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